Stay updated on Sotatercept in ESRD Hemodialysis: Clinical Trial

Sign up to get notified when there's something new on the Sotatercept in ESRD Hemodialysis: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Sotatercept in ESRD Hemodialysis: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the data related to a Phase 2a study evaluating the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of Sotatercept (ACE-011) for correcting anemia in subjects with end-stage renal disease on hemodialysis.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:51.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for study participants, specifying that males or females aged 18 or older on hemodialysis for at least 12 weeks and on a stable dose of Erythrocyte Stimulating Agents are eligible. Previously, the page only listed dates related to study record updates.
    Difference
    21%
    Check dated 2024-05-22T21:17:33.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:33:03.000Z thumbnail image

Stay in the know with updates to Sotatercept in ESRD Hemodialysis: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Sotatercept in ESRD Hemodialysis: Clinical Trial page.